Vanda Pharmaceuticals Inc.
VNDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001347178
No open-market purchases or sales by Vanda Pharmaceuticals Inc. insiders were filed in the last 90 days; 172 institutions reported holding it in 13F filings for Q2 2026, worth $304.1M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Vanda Pharmaceuticals Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 189 | 1 | 181 | −7 |
| Shares | 54.6M | 20.0K | 54.9M | +303.6K (+0.6%) |
| Value | $820.0M | $300.0K | $1.18B | +$359.5M (+43.9%) |
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Vanda Pharmaceuticals Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Arrowstreet Capital, Limited Partnership | 421,422 | $9.06M | 0.01% |
| Bridgeway Capital Management, LLC | 142,600 | $3.07M | 0.05% |
| FinTrust Capital Advisors, LLC | 101,647 | $2.19M | 0.58% |
| Allianz Asset Management GmbH | 42,141 | $907.0K | 0.00% |
| Sit Investment Associates Inc | 31,150 | $670.0K | 0.02% |
| Amalgamated Bank | 27,102 | $583.0K | 0.00% |
| AXA S.A. | 26,300 | $566.0K | 0.00% |
| Guggenheim Capital LLC | 22,287 | $479.0K | 0.00% |
| Walleye Trading LLC | 21,617 | $465.0K | 0.01% |
| HFR Wealth Management, LLC | 20,000 | $430.0K | 0.13% |
| Ci Investments Inc. | 14,193 | $305.0K | 0.00% |
| Profund Advisors LLC | 10,855 | $231.0K | 0.01% |
| State of Wyoming | 10,182 | $219.0K | 0.14% |
| FORA Capital, LLC | 5,990 | $129.0K | 0.02% |
| Sutton Wealth Advisors Inc. | 446 | $9.59K | 0.00% |
| Rockefeller Capital Management L.P. | 200 | $4.00K | 0.00% |
Sold out (23)
Institutions that held Vanda Pharmaceuticals Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
Not filed for Q2 2021 yet (1)
Institutions that held Vanda Pharmaceuticals Inc. at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Reilly Herbert Faulkner III | 20,000 | $300.0K |